SequelSEC

ADMA BIOLOGICS, INC. ADMA

Biological Products, (No Diagnostic Substances) · CIK 0001368514 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$512.28M
Fiscal year ended 2026-06-30
Operating income
$224.48M
Fiscal year ended 2026-06-30
Free cash flow
$116.47M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$4.23BMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$17.76Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income28.8×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue8.3×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity8.9×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue0.9%1th
Operating margin37.5%96th
SBC / revenue3.9%9th
Net margin28.8%89th
FCF margin5.5%84th
Long-term debt / equity0.15x27th
Effective tax rate19.6%65th
Current ratio6.71x64th
Revenue YoY growth19.6%60th
Gross margin57.4%41th
CapEx / revenue4.4%57th

ADMA BIOLOGICS, INC. (ADMA) reported revenue of $512.28M and net income of $168.96M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ADMA BIOLOGICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

ADMA BIOLOGICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$512.28M
Cost of revenue$180.81M
Gross profit$331.47M
Operating income$224.48M
Net income$168.96M
Research & development$11.52M
Weighted-average diluted sharesUnavailable
Pretax income$216.47M
Income tax expense$47.52M
Diluted EPSUnavailable
Selling, general & administrative$98.77M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

ADMA BIOLOGICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$136.02M
Total assets$684.21M
Current assets$528.20M
Total liabilities$276.00M
Current liabilities$75.76M
Total equity incl. NCI$408.21M
Temporary (mezzanine) equityUnavailable
Inventory$239.31M
Accounts receivable$138.23M
Goodwill$3.53M
Long-term debt$192.84M
Accounts payable$31.72M

Cash flow

ADMA BIOLOGICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$136.72M
Capital expenditures$20.25M
Investing cash flow-$14.50M
Financing cash flow-$76.49M
Net change in cash$45.74M
Stock-based compensation$22.90M
Common dividends paidUnavailable
Common share repurchases$187.18M
Depreciation & amortization$7.55M

Derived

ADMA BIOLOGICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow$116.47M
Gross margin64.7%
Operating margin43.8%
FCF margin22.7%
SBC / revenue4.5%
Current ratio6.97x
Revenue YoY growth8.0%
Net margin33.0%
R&D / revenue2.2%
CapEx / revenue4.0%
Long-term debt / equity0.47x
Effective tax rate22.0%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ADMA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-02-25View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADPT AGEN AGTX AIM ALEC ALGS ALLO AMGN

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.